adenine has been researched along with Nail Diseases in 3 studies
Nail Diseases: Diseases of the nail plate and tissues surrounding it. The concept is limited to primates.
| Excerpt | Relevance | Reference |
|---|
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bitar, C | 1 |
| Farooqui, MZ | 1 |
| Valdez, J | 1 |
| Saba, NS | 1 |
| Soto, S | 1 |
| Bray, A | 1 |
| Marti, G | 1 |
| Wiestner, A | 1 |
| Cowen, EW | 1 |
| Xiao, SX | 1 |
| Feng, YG | 1 |
| Ren, XR | 1 |
| Tan, SS | 1 |
| Li, L | 1 |
| Wang, JM | 1 |
| Shi, YZ | 1 |
| Uchida, T | 1 |
| Inaoki, M | 1 |
| Makino, E | 1 |
| Fujimoto, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of PCI-32765 for Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Need Therapy and Are Older Than 65 or Have a 17p Deletion[NCT01500733] | Phase 2 | 86 participants (Actual) | Interventional | 2012-01-05 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The primary endpoint was response after 6 cycles of therapy. Overall response rate was calculated as complete response plus partial response, based on the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2008 criteria.as follows:~Complete response (CR): all group A and group B criteria are met~Group A criteria: resolution of enlarged lymph nodes, normal size spleen and liver, absolute lymphocyte count < 4,000/uL, normocellular bone marrow with < 30% lymphocytes without nodules~Group B criteria: improved blood count (platelet count > 100,000/uL, hemoglobin > 11.0 g/dL, neutrophils > 1,500/uL)~Partial response (PR): at least 2 of the group A criteria plus one of the group B criteria are met~Group A criteria: >=50% decrease in target lymph nodes, >=50% decrease in spleen size, >=50% decrease in liver size, 50% reduction in marrow infiltrates~Group B criteria: platelet count > 100,000/uL, hemoglobin > 11.0 g/dL, neutrophils > 1,500/uL" (NCT01500733)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Elderly Cohort | 93.9 |
| TP53 Cohort | 95.8 |
1 trial available for adenine and Nail Diseases
| Article | Year |
|---|---|
Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Female | 2016 |
2 other studies available for adenine and Nail Diseases
| Article | Year |
|---|---|
A novel mutation in the second half of the keratin 17 1A domain in a large pedigree with delayed-onset pachyonychia congenita type 2.
Topics: Adenine; Age of Onset; Amino Acid Substitution; Asparagine; Aspartic Acid; Base Sequence; Codon; Fem | 2004 |
Identification of a recurrent mutation in keratin 17 in a Japanese family with pachyonychia congenita type 2.
Topics: Adenine; Adult; Amino Acid Sequence; Asian People; Base Sequence; Guanine; Humans; Keratins; Male; M | 2005 |